STAT3 and non-small cell lung carcinoma: The combined treatment of Artemisia santolinifolia (AS) and Docetaxel (DTX) exhibits a synergistic impact on NSCLC by suppressing STAT3 signaling, resulting in reduced phosphorylation of STAT3 and consequent downregulation of survivin, a protein associated with cell survival.